A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)
Start Date
6/16/2026
Completion Date
3/1/2030
Summary
This study is designed to evaluate the safety and tolerability of NVC-001 in adults with LMNA-related dilated cardiomyopathy (LMNA-DCM). The study will also assess exploratory measures of efficacy.
Detailed Description
This is a Phase 1/2, open-label study of NVC-001 in adults with LMNA-related dilated cardiomyopathy (LMNA-DCM). The primary objective is to evaluate the safety and tolerability of NVC-001. Secondary and exploratory objectives include characterization of pharmacodynamic effects and assessment of preliminary efficacy.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
NVC-001 - Low Dose
NVC-001 - Intermediate Dose
NVC-001 - High Dose
Conditions
Locations
University of Alabama in Birmingham
Birmingham, Alabama 35294
United States
Cedars-Sinai Medical Center
Los Angeles, California 90048
United States
Brigham and Women's Hospital
Boston, Massachusetts 02115
United States
Mayo Clinic
Rochester, Minnesota 55905
United States
The Christ Hospital
Cincinnati, Ohio 45219
United States
Houston Methodist Hospital
Houston, Texas 77030
United States